Central tolerance plays a critical role in eliminating self-reactive T cells specific for peripheral antigens. Here we show that central tolerance of MHC class I-restricted T cells specific for classic myelin basic protein (MBP), a component of the myelin sheath, is mediated by both bone marrow (BM)-derived and nonBM-derived cells. Unexpectedly, BM-derived cells induce tolerance directly by using classic MBP that they synthesize, whereas nonBM-derived cells mediate tolerance by crosspresenting classic MBP acquired from an exogenous source. Thus, tolerance to tissue-specific antigens can involve multiple cell types and mechanisms in the thymus, which may account for the limited spectrum of autoimmune syndromes observed when expression of tissue-specific antigens is impaired only in thymic epithelial cells.
D
efining the mechanisms that maintain tolerance to tissuespecific antigens (TSAs) is critical for understanding the pathogenesis of organ-specific autoimmune diseases such as multiple sclerosis (MS). Tolerance of many TSAs occurs in the thymus and is facilitated by medullary thymic epithelial cells (mTECs) that promiscuously express a broad range of TSAs (1) . TSAs synthesized and presented by mTECs can induce tolerance in the MHC class I and II pathways (2, 3) . In addition, bone marrow (BM)-derived cells can acquire TSAs from mTECs and induce both CD4 ϩ and CD8 ϩ T cell tolerance (2, 4) . However, in vivo studies indicate that, under physiological conditions, only BM-derived cells acquire sufficient TSA from exogenous sources to negatively select MHC class II-restricted T cells (3, 5) .
We investigated the mechanisms that induce central tolerance to myelin basic protein (MBP), which is believed to be targeted by self-reactive T cells in MS. The genetic organization of the MBP locus may influence how tolerance is induced to this self-antigen. The MBP locus encodes two separate protein families that are transcribed by using different promoters, both of which generate multiple isoforms via alternative splicing (6) . One family consists of MBP isoforms that are incorporated into myelin (classic MBP) and are considered TSAs because of their restricted expression in myelin-forming cells. Proteins in the other family (golli MBP) modulate calcium influx (7, 8) and are expressed in the nervous system, thymus, and peripheral lymphoid tissues (6) . Although the two families differ functionally, classic and golli MBP are immunologically related because they contain stretches of identical amino acid sequence because of exon sharing (6) . Thus, expression of golli MBP in the thymus could mediate negative selection of many classic MBP-specific T cells.
We sought to define tolerance mechanisms for CD4 ϩ and CD8 ϩ MBP-specific T cells because both subsets mediate autoimmunity (5, 9, 10) . We previously found that CD4 ϩ MHC class II-restricted T cells specific for MBP121-140, an epitope present in classic but not golli MBP, undergo central tolerance mediated by BM-derived cells that acquire classic MBP from a nonBMderived source, most likely degraded myelin (5). TECs did not induce tolerance in these T cells. CD8 ϩ MHC class I-restricted thymocytes specific for MBP79-87, an epitope in both classic and golli MBP, are also deleted in the thymus (11) . We analyzed tolerance in this system by using MBP79-87-specific T cell receptor (TCR) transgenic (8.6) mice, MBP-deficient (MBP Ϫ/Ϫ ) mice that do not express any golli or classic MBP isoforms containing MBP79-87 (12) , and golli-deficient (golli Ϫ/Ϫ ) mice that have unaltered classic MBP expression but do not express any golli isoforms (13) . We found that classic MBP synthesized by nonBM-derived cells was sufficient to tolerize MBP79-87-specific T cells (11) ; however, the source of classic MBP, the cell types presenting this epitope, and the role of golli in tolerance induction were not investigated.
Here we show that expression of either golli or classic MBP is sufficient to mediate efficient deletion of CD8 ϩ MBP79-87-specific T cells, but distinct mechanisms are used for the different MBP families. BM-derived cells mediate central tolerance by synthesizing and directly presenting MBP79-87 derived from classic MBP. Thus, BM-derived cells can be tolerogenic via promiscuous expression of a TSA. NonBM-derived cells, which we refer to as TECs because these are the major nonhematopoietic antigen-presenting cells (APCs) in the thymus, induce tolerance by using golli MBP that they synthesize and present directly. However, TECs do not mediate deletion via synthesis and direct presentation of classic MBP. Instead, our studies reveal a mechanism of central tolerance in which TECs crosspresent exogenous classic MBP in the MHC class I pathway. Together, these results identify multiple mechanisms that profoundly expand the ability to induce TSA-specific central tolerance.
Results
Classic MBP Is Tolerogenic Before Myelination. Thymocytes in MHC class I-restricted MBP79-87-specific 8.6 TCR transgenic mice on a WT (MBP ϩ/ϩ ) background are deleted at a late stage of maturation, manifested by a loss of mature CD8 single-positive (SP) HSA (CD24) lo CD3 ϩ thymocytes (11) . To define the role of classic MBP in this central tolerance, we bred 8.6 mice onto the golli Ϫ/Ϫ background. Positive selection is observed in 8.6 MBP Ϫ/Ϫ mice, whereas extensive negative selection is seen in both MBP ϩ/ϩ and golli Ϫ/Ϫ 8.6 mice, confirming that classic MBP is sufficient to mediate tolerance ( Fig. 1 A-C) . Classic MBP transcripts are detected only at very low levels in the neonatal nervous system, and classic MBP proteins are not detected until day 6 or later, coinciding with the beginning of active myelination (14) . Therefore, to determine whether 8.6 T cell tolerance depends on classic MBP derived from myelin, we analyzed 3-day-old mice. Surprisingly, both 3-day-old MBP ϩ/ϩ and golli Ϫ/Ϫ 8.6 mice exhibited strong negative selection, whereas 3-day-old MBP Ϫ/Ϫ 8.6 mice exhibited positive selection ( Fig. 1  D-F not present it because of the lack of MHC class I molecules. No deletion was observed in these chimeras (Fig. 2D ), indicating that negative selection does not occur via crosspresentation of BMderived MBP by TECs. The absence of negative selection in these chimeras also indicates that ␤2m Ϫ/Ϫ BM-derived cells do not acquire ␤2m from host cells. We could not determine whether golli MBP synthesis by BM-derived cells is sufficient to induce tolerance because there are no mouse models that express golli but not classic MBP. However, negative selection occurred when 8.6 golli Ϫ/Ϫ BM was transplanted into MBP Ϫ/Ϫ mice, indicating that classic MBP synthesized and presented by BM-derived cells is sufficient to induce efficient central tolerance (Fig. 2E) Fig. 3 A  and B) . We then asked whether TEC presentation of MBP produced by nonBM-derived cells was sufficient to induce tolerance by transplanting 8.6 ␤2m Ϫ/Ϫ MBP Ϫ/Ϫ BM, which lacks both MBP and MHC class I expression, into MBP Ϫ/Ϫ , MBP ϩ/ϩ , and golli Ϫ/Ϫ recipients. Positive selection was observed in the control MBP Ϫ/Ϫ recipients, but negative selection occurred in both MBP ϩ/ϩ and golli Ϫ/Ϫ recipients ( Fig. 3 C-E) , demonstrating that TECs induce tolerance by using a nonBM-derived source of classic MBP. The extent of deletion was similar in all cases with no significant difference in the average percentage of CD8 SP HSA lo thymocytes (P Ͼ 0.2, Fig. 3F ). The classic MBP presented by TECs could be synthesized by TECs themselves as part of their program of promiscuous gene expression, or it could come from an exogenous source such as myelin. Golli MBP may also contribute to TEC-mediated tolerance as golli transcripts have been detected in TECs (17) . To address these questions, we generated BM chimeras in thymectomized recipients that were given thymus grafts to restrict MBP synthesis to nonBM-derived cells in either the thymus or periphery. Development of 8.6 thymocytes was normal in the thymus grafts, as shown by positive selection when 8.6 ␤2m Ϫ/Ϫ MBP Ϫ/Ϫ BM was transplanted into thymectomized MBP Ϫ/Ϫ mice containing a MBP Ϫ/Ϫ thymus graft and by negative selection when the same BM was transplanted into thymectomized MBP ϩ/ϩ mice containing a MBP ϩ/ϩ thymus graft (Fig. 4 A and B) . In BM chimeras in which synthesis of golli and classic MBP was restricted to nonBM-derived cells within the thymus graft, 8.6 thymocytes were deleted, indicating that synthesis and presentation of golli and/or classic MBP by TECs is sufficient to mediate tolerance (Fig. 4C) . To determine which tolerogenic MBP family is synthesized by TECs, identical BM chimeras were generated by using golli Ϫ/Ϫ thymus grafts such that only classic MBP could be synthesized by TECs. Positive selection was observed in these animals, indicating that TECs cannot synthesize classic MBP in sufficient quantities to mediate deletion of 8.6 thymocytes (Fig. 4D) . This result also demonstrates that golli proteins mediate the negative selection seen in MBP ϩ/ϩ thymus grafts (Fig. 4C ). These functional data demonstrating that TECs do not synthesize tolerogenic classic MBP are consistent with the observation that mTECS synthesize golli but not classic MBP (1, 17) . Together with our previous data showing that TECs induce 8.6 thymocyte deletion by presenting classic MBP obtained from a nonBM-derived source (Fig. 3E ), these data demonstrate that TECs acquire classic MBP and crosspresent it in the MHC class I pathway. The fact that TECs do not acquire classic MBP from BMderived cells (Fig. 2D) indicates that the antigen must be obtained from myelin. Because the thymus is innervated, classic MBP could be acquired from myelin within the thymus. Alternatively, degraded myelin from the periphery could enter the thymus either as a bloodborne antigen or via APCs that acquire the antigen in the periphery. To investigate these possibilities, we transplanted 8.6 ␤2m Ϫ/Ϫ MBP Ϫ/Ϫ BM into thymectomized MBP ϩ/ϩ mice containing a MBP Ϫ/Ϫ thymus graft. Positive selection of 8.6 thymocytes was observed in these BM chimeras, indicating that TECs do not acquire sufficient MBP from the blood to induce tolerance (Fig. 4E) . Although the MHC class I-deficient APCs could still acquire exogenous MBP from the blood or periphery in these chimeras, the positive selection observed confirms our earlier result that TECs do not mediate negative selection by using MBP obtained from APCs (Fig. 2D) . We then generated identical experimental animals except that the 8.6 MBP Ϫ/Ϫ BM was not ␤2m deficient. Positive selection of 8.6 thymocytes was again observed (Fig. 4F) , indicating that central tolerance to MHC class I-restricted MBP-specific T cells is not induced by BM-derived cells presenting MBP acquired from the blood or periphery. Together, these data demonstrate that TECs use two redundant mechanisms to tolerize MHC class I-restricted MBP79-87-specific cells: they synthesize and directly present MBP79-87 derived from golli MBP, and they crosspresent MBP79-87 derived from classic MBP acquired from myelin in situ. This latter mechanism is disrupted in thymus grafts, likely because of the unmyelinated status of the graft obtained from embryonic or neonatal donors, suggesting that the anatomical location and/or amount of myelinated nerve fibers within a nonmanipulated thymus is critical for TECs to acquire classic MBP.
Discussion
Our studies revealed two novel mechanisms of central tolerance to a naturally expressed TSA. First, we found that synthesis and direct presentation of classic MBP by BM-derived cells is sufficient to mediate central tolerance in the MHC class Irestricted pathway. Although this result was surprising, expression of natural TSAs in BM-derived cells has been reported before (18) (19) (20) (21) , and a low level of classic MBP expression has been observed in splenic macrophage (22) . However, TSA expression in the thymus does not ensure tolerance (23) , and in previous studies in which BM-derived cells were the only source of TSA in the thymus, tolerance was either incomplete (20) or only occurred in the periphery (24) . Our studies provide evidence that, under physiological conditions, BM-derived cells can induce central tolerance by direct presentation of a naturally occurring TSA in the MHC class I pathway. Interestingly, BM-derived cells do not use the classic MBP that they synthesize to present MHC class II-restricted MBP121-140, as CD4 ϩ T cell tolerance to this epitope is mediated exclusively by classic MBP acquired by BM-derived cells (5) . This may reflect either differences in the abundance of MBP isoforms containing MBP121-140 compared to MBP79-87 or a reduced efficiency of BM-derived cells to present MHC class II-restricted epitopes derived from endogenously synthesized antigen. Regardless of the reason, the difference between CD4 ϩ vs. CD8 ϩ T celltolerance mechanisms has important consequences for establishing tolerance to classic MBP during development. Because BM-derived cells must acquire MBP from myelin to negatively select CD4 ϩ MBP121-140-specific T cells, the extent of tolerance to this epitope parallels the gradual rate of myelination, which begins after day 6 and is not complete until 10 weeks of age (5) . In contrast, strong tolerance mediated by classic MBP is already established in 3-day-old mice for MHC class I-restricted MBP-specific T cells. This result differs from a report of impaired central tolerance to a MHC class I-restricted TSA in neonatal vs. adult mice (25) . Our findings suggest that the efficiency of central tolerance in young mice may depend on direct presentation of TSAs by BM-derived cells. The CD8 ϩ T cell tolerance to classic MBP that we observe in 3-day-old 8.6 golli Ϫ/Ϫ mice is likely mediated by BM-derived cells because TEC-mediated tolerance depends on acquiring classic MBP from myelin, which is not available in neonates. In contrast, the TSA that induced incomplete neonatal CD8 ϩ T cell-central tolerance required direct presentation by TECs or crosspresentation by BM-derived cells that acquired antigen from TECs. Thus, the synthesis and direct presentation of TSAs by BMderived cells may facilitate induction of CD8 ϩ T cell tolerance during ontogeny.
Another surprising finding from our studies is that nonBMderived cells, presumably TECs, mediate negative selection by acquiring exogenous classic MBP and crosspresenting it in the MHC class I pathway. To our knowledge, this is a unique demonstration of tolerance induced in vivo to a naturally occurring TSA via crosspresentation by TECs. Negative selection is as efficient when antigen presentation is restricted to this mechanism alone as it is in intact 8.6 MBP ϩ/ϩ mice in which both classic and golli MBP are presented by multiple cell types (P ϭ 0.3 when comparing the average percentage of CD8 SP HSA lo thymocytes in 8.6 MBP ϩ/ϩ mice to mice in which only classic MBP is crosspresented by TECs). The mechanism of MBP uptake by TECs is not yet known. APCs acquire exogenous antigen via several routes, including phagocytosis, endocytosis, and antigen transfer via exosomes and gap junctions. Endocytic mechanisms mediated by distinct receptors can direct soluble antigen into either early or late endosomes such that presentation occurs only in the MHC class I or class II pathway, respectively (26) . However, we show that MBP is not acquired as a soluble, bloodborne antigen, and the mannose receptor, which directs antigen to early endosomes and predominant MHC class I presentation, is not detected on TECs (27) . Because MBP crosspresentation by TECs occurs only in a nongrafted thymus, and TECs do not acquire classic MBP from BM-derived cells, it is likely that classic MBP is acquired directly from myelin in situ and that this access is disrupted in the thymus graft. This source is consistent with studies indicating that long-lived, stable proteins, rather than peptides, are the predominant source of crosspriming antigen in vivo (28, 29) . Acquisition of cell or membrane-associated protein occurs via phagosomes, and crosspresentation requires active alkalization of the phagosome to prevent protein degradation before antigen export to the cytoplasm (26) . However, increasing acidification of the phagosome and activation of lysosomal proteases typically results in loading peptides derived from the same antigen onto MHC class II molecules. Therefore, it is surprising that TECs do not induce tolerance to the MHC class II-restricted classic MBP121-140 epitope, as presentation of exogenous antigen in the MHC class II pathway is usually more efficient than crosspresentation in the MHC class I pathway. This difference could reflect dependence by TECs on a nonphagosomal mechanism of antigen acquisition, such as peptide transfer via exosomes or gap junctions mediated by proximity of TECs to the cytosolic processes of myelinforming Schwann cells. Interestingly, MBP synthesis occurs within myelin membranes distal to the cell body because of translocation of MBP-encoding RNA from the nucleus to myelinating cytoplasmic processes (30) . Translation is arrested while the RNA is transported, and the subsequent initiation of translation within the myelinating processes could result in localized production of classic MBP-derived defective ribosomal products (DRiPs) (31) . If proteosomal degradation products of MBP DRiPs are transferred from myelin membranes to TECs, MHC class I presentation would be favored. Alternatively, lack of MBP121-140 presentation by TECs may reflect the lower abundance of classic MBP isoforms containing MBP121-140 compared to MBP79-87. The 14-kDa classic MBP isoform, which includes MBP79-87 but not MBP121-140, is the most abundant isoform in murine myelin and it continues to accumulate during myelin formation after synthesis of the other isoforms reach steady state (32) . Therefore, our data do not exclude potential processing of exogenous MBP by TECs and presentation of other epitopes in the MHC class II pathway.
Our studies demonstrate multiple, redundant mechanisms for mediating tolerance to MHC class I-restricted MBP79-87, including novel mechanisms used by both BM-derived cells and TECs. Interestingly, negative selection appears to occur to the same extent and at the same late stage of thymocyte maturation regardless of the cell-type presenting MBP or the source of antigen. This suggests that either the different APCs presenting MBP79-87 are only encountered after the double-positive stage, or CD8 ϩ thymocytes must reach this stage of development to be susceptible to negative selection.
Materials and Methods
Mice. C3HeB/FeJ (C3H), C3Fe.SWV-Mbp shi /J (MBP Ϫ/Ϫ ), and C3.129P2(B6)-B2m tm1Unc /J (␤2m Ϫ/Ϫ ) mice were from The Jackson Laboratory. TCR-transgenic (8.6) mice have been described previously (11) . Golli Ϫ/Ϫ mice were a kind gift from A. Campagnoni (University of California, Los Angeles) and were backcrossed 10 generations onto the C3H background, except for the 6-week-old 8.6 golli Ϫ/Ϫ mice in Fig. 1C (gen. 5) , the 8.6 golli Ϫ/Ϫ BM donors in Fig. 2E (gen. 5), and the golli Ϫ/Ϫ recipients in Fig. 3B (gen. 4) . All mice were bred and maintained in a specific pathogen-free facility at the University of Washington. All procedures were approved by the Institutional Animal Care and Use Committee at the University of Washington.
Flow Cytometry. Thymocytes (1-5 ϫ 10 6 ) were stained with fluorescently conjugated antibodies specific for CD3, CD4, CD8, HSA (CD24), V␣8, V␤6, or K k and analyzed by four-color flow cytometry on a FACScan LSR or six-color flow cytometry on a FACSCanto (BD Biosciences). All antibodies were purchased from BD Biosciences except CD8-PETR (Caltag Laboratories).
BM Chimeras. BM cells (1 ϫ 10 7 ) depleted of T and B cells by Dynal bead separation (Dynal) with anti-Thy1.2-, TCR-, and B220-biotin antibodies (BD Biosciences) were transferred into lethally irradiated mice (1,000 rads on day Ϫ1). Recipients were provided neomycin sulfate (2 mg/ml, Sigma) in their drinking water from day Ϫ2 to day 14 and were analyzed 6 -8 weeks later. For BM chimeras involving MHC class I-deficient BM, NK cell depletion of recipient mice by i.v. administration of antiasialo GM1 antibody (25 l, Wako Chemicals USA, Inc.) was performed 1 day before BM transplantation (on day Ϫ1).
Thymus Transplantation and Thymectomy. One to two thymic lobes from embryonic day-15-21 fetuses or neonatal day-0 -2 mice were inserted under the kidney capsule of 4-to 6-week-old recipient mice under anesthesia (isoflurane) and provided with postoperative analgesia (carprofen, 5 mg/kg) for a minimum of 48 h. Thymus transplantation was immediately followed by thymectomy. Mice were used as recipients to generate BM chimeras 2-4 weeks after surgery.
Statistical Analysis. All P-values were calculated with a Student's t test.
